The operating system for biotech CFOs.
AI-native software for SEC filings, capital strategy, investor relations, and catalyst planning. Built for emerging biotech finance teams who can't afford a 50-vendor stack.
For sub-$1B publicly traded biotech.
What biotech CFOs actually deal with
Filings drafted at midnight
Drafting 8-Ks, S-3s, and Form Ds the night before they're due, then redlining with counsel for $5-10K per filing. Repeat 20-30 times per year.
Calendars across six systems
Clinical milestones in one spreadsheet, FDA dates in another, financing windows in email, conferences in Outlook, ATM blackouts in the broker's portal, board meetings in Calendly.
Investor research from scratch every time
Pulling 13F filings, prior PIPE participation, fund mandates, and ticket size history into a spreadsheet for each new capital raise. Repeat for each raise.
Board decks from raw data
Assembling quarterly board materials from cap table software, accounting exports, IR vendor portals, and pipeline updates. 20-40 hours per quarter just to compile.
One platform. The whole finance and IR stack.
Filings Automation
AI-drafted first versions of every 8-K, S-3, and Form D — ready for counsel review in minutes, not hours.
Learn moreCapital Strategy Modeling
Model financing scenarios against your clinical timeline. See dilution, runway, and optimal financing timing in one view.
Learn moreInvestor Research and CRM
Track institutional mandates, sell-side coverage, and your relationships. Search investors by ticket size, prior PIPE participation, and sector mandate.
Learn moreCatalyst Calendar
Clinical milestones, FDA dates, financing windows, lockup expirations, conferences, and ATM blackouts in one calendar with conflict detection.
Learn moreBuilt by biotech capital markets operators.
[Founder Name] started his career in micro-cap biotech capital markets at Aegis Capital, then joined Robinhood's options and margin team before founding Veles. He's currently pursuing a medical degree with a focus on oncology — the same disease area many of our customers are working to treat.
Veles was built from frustration with how broken biotech finance and IR operations actually are. We're building the platform we wished existed when we were on the other side of the table.